



Jackson Hole Fire/EMS Operations Manual

Approved by: [Signature]
Will Smith, MD, Medical Director

Approved by: [Signature]
Brady Hansen, Chief

Title: **Medication Protocol:
Tranexamic Acid**

Division: 17

Article: 1.34

Revised: March 2021

Pages: 1

Tranexamic Acid (TXA) (Medication Protocol)

PARAMEDIC PROVIDERS

STANDING ORDER

CLASS: Antifibrinolytic

PHARMACOLOGY/ Competitively inhibits activation of plasminogen, reducing conversion of
ACTIONS: plasminogen to plasmin. At higher doses, directly inhibits plasmin activity.
With massive bleeding, this may help stabilize clot formation and decrease
extravascular bleeding.

ONSET/DURATION: Onset: 5-15 minutes / Duration: 3 hours

USE IN FIELD/
INDICATIONS:

- Penetrating wounds to **neck to mid-thigh (anterior, posterior, or both)** with anticipated significant blood loss.
- **Suspected** severe internal injuries from blunt trauma.
- Other causes of moderate to severe **hemorrhagic shock less than 3 hours old** with suspected need for transfusion due to internal or external blood loss.
 - Tachycardia- HR >110
 - Hypotension- SBP <90 mmHg, Pedi <70 + (age in yrs. x 2)

CONTRAINDICATIONS: Non-hemorrhagic shock and active intravascular clotting (DVT, PE).

SIDE EFFECTS: Impaired color vision, allergic reactions, thrombotic events, hypotension, nausea, vomiting, diarrhea.

ROUTE: IV/IO

DOSAGE:

ADULT	PEDIATRIC (<45 kg)
2 grams slow IV push.	15 mg/kg slow IV push.

DO NOT Exceed Adult Dose

PREGNANCY SAFETY: Category B- no proven risk to humans.

COMMENTS: Delayed effects can be seen up to 48 hours after administration consistent with anti-inflammatory actions.